arrow
R

Rikke Hedegaard Dahlrot

University of Southern Denmark
H指数:22
被引数:1,688

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

MAPPING ISOLATED LOCAL PROGRESSION IN NEWLY DIAGNOSED GLIOBLASTOMA TO INFORM ON A CLINICAL TARGET VOLUME MARGIN FOR A RADIATION BOOST TARGET

绘制新诊断胶质母细胞瘤中孤立局部进展的图谱,以指导放射增敏目标靶区的临床靶区边界。

2025-11-010
OAAI
EXPLORING A PERSONALIZED CLINICAL TARGET VOLUME MARGIN IN GLIOBLASTOMA RADIOTHERAPY USING RECURRENCE PATTERNS IN A NATIONWIDE COHORT

探索基于全国队列复发模式制定个性化胶质母细胞瘤放疗临床靶区边界

2025-11-010
OAAI
Evaluating Measurement Stability in Glioblastomas Using Magnetic Resonance Elastography: Repeatability and Interobserver Agreement

评估胶质母细胞瘤中磁共振 elastography 测量稳定性的研究:重复性和观察者间一致性

2025-10-080
PRE
A PHASE 2 STUDY OF PEMIGATINIB FOR PRE-TREATED GLIOBLASTOMA OR OTHER GLIOMAS WITH ACTIVATING FGFR1-3 ALTERATIONS: FINAL RESULTS FROM FIGHT-209

一项关于佩米加替尼治疗经治胶质母细胞瘤或其他携带激活性FGFR1-3变异的胶质瘤的II期研究:FIGHT-209的最终结果

2025-10-010
OAAI
Health-related quality of life and cognitive functioning in survivors of oligodendroglioma: An international cross-sectional investigation

健康相关生活质量及认知功能在寡形胶质细胞瘤幸存者中的表现:一项国际横断面调查

2025-08-011
OAAI
Mapping cell density and hypoxia in glioblastoma using time-dependent diffusion MRI: improved cell density assessment compared to conventional diffusion metrics

利用时变扩散MRI映射胶质母细胞瘤中的细胞密度和缺氧:与常规扩散指标相比,提高了细胞密度评估

2025-07-170
PRE
Recommendations for radiotherapy quality assurance in clinical trials

临床试验中放射治疗质量保证的建议

2025-05-220
OA
Dose-enhanced versus standard TTFields for first recurrence of glioblastoma: A randomized phase 2 clinical trial

剂量增强型与标准TTFields治疗胶质母细胞瘤首次复发的比较:一项随机Ⅱ期临床试验

2025-01-010
OAAI
HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
2024-11-110
PRE
OPTIMIZING TUMOR TREATING FIELDS THERAPY FOR FIRST RECURRENT GLIOBLASTOMA WITH SKULL REMODELING SURGERY. FINAL RESULTS FROM OPTIMALTTF-2, A MULTI-CENTER, RANDOMIZED, CLINICAL TRIAL
2024-11-110
PRE
HEALTH-RELATED QUALITY OF LIFE AND COGNITIVE FUNCTIONING IN SURVIVORS OF OLIGODENDROGLIOMA: AN INTERNATIONAL CROSS-SECTIONAL INVESTIGATION
2024-10-170
PRE
Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib/II study
2023-10-010
OA